CN1720965A - Chinese medicinal composition for treating acute icterohepatitis - Google Patents
Chinese medicinal composition for treating acute icterohepatitis Download PDFInfo
- Publication number
- CN1720965A CN1720965A CN 200510049897 CN200510049897A CN1720965A CN 1720965 A CN1720965 A CN 1720965A CN 200510049897 CN200510049897 CN 200510049897 CN 200510049897 A CN200510049897 A CN 200510049897A CN 1720965 A CN1720965 A CN 1720965A
- Authority
- CN
- China
- Prior art keywords
- herba
- raw material
- treatment
- poria
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a Chinese medicinal composition for treating acute icterohepatitis, which comprises the following constituents (by weight portion), oriental wormwood 1-40, giant knotweed rhizome 1-30, Hypericum japonicum Thunb. 1-30, root of large-flowered skullcap 1-22, poria cocos wolf 1-28.
Description
One, affiliated technical field
The present invention relates to a kind of Chinese medicine composition for the treatment of hepatitis, refer in particular to a kind of Chinese medicine composition for the treatment of acute icterohepatitis.
Two, background technology
Acute icterohepatitis is higher at China's sickness rate, see with hepatitis A patient (HAV) infection more, the course of disease can be divided into matter subcutaneous ulcer early stage, stage of icterus and convalescent period three phases, last for 2～April, Acute onset, fear of cold heating, malaise, inappetence, detest oil, feel sick, vomiting and epigastric discomfort, abdominal distention and pain, diarrhoea, pain in the hepatic region, abnormal liver function etc.Upper airway symptoms can be arranged, and the urine color is deepened gradually.Xanthochromia occurs to stage of icterus skin sclera, urine also can have the complexion changed of stool shallow, diseases such as skin sufferings as strong tea.Liver enlargement this moment has tenderness and percussion pain, convalescent period jaundice disappear transference cure, liver and spleen retraction, liver function recovery.Acute icterohepatitis, the traditional Chinese medical science think that eating and drinking without temperance, damp and hot heresy are outer and invade or the epidemic disease poison infects, cause irritability lose dredge, the bile flowing outside the biliary passages, taste be impaired.Clinical manifestation icteric sclera, skin Huang, heating, thirsty, nausea and vomiting, hypochondriac pain, yellow urine, yellowish fur, the stringy and rolling pulse number of holding concurrently belongs to YANG jaundice.In the treatment based on clearing away heat-damp and promoting diuresis, depressed liver-energy dispersing and function of gallbladder promoting.That Chinese patent once disclosed was a kind of " Chinese medicine of treatment acute icterohepatitis and preparation method thereof " (application number: 2003101104902, publication number: CN1541691A, open day: on November 3rd, 2004), comprise following component by weight percentage: Herba Desmodii Styracifolii 10%-80%, Rhizoma Polygoni Cuspidati 5%-60%, Spica Prunellae 5%-30%, Poria 0-20%, Fructus Jujubae 0-10%.
Three, summary of the invention
The object of the present invention is to provide a kind of therapeutic effect remarkable, the medicine source is extensive, the Chinese medicine composition of treatment acute icterohepatitis with low cost.
For achieving the above object, the solution that the present invention takes is: a kind of Chinese medicine composition for the treatment of acute icterohepatitis, it is made up of the following weight proportion raw material: Herba Artemisiae Scopariae 1-40, Rhizoma Polygoni Cuspidati 1-30, Herba Hyperici Japonici 1-30, Radix Scutellariae 1-22, Poria 1-28.
Among the present invention: the various active ingredients of Herba Artemisiae Scopariae; the bile secretion of promotion and the effect of row's gallbladder are arranged; rats'liver damage due to the carbon tetrachloride there is protective effect; blood pressure lowering, blood fat reducing, anticoagulant are arranged and promote Fibrinolytic effect; antineoplastic action (its mechanism for the propagation of direct killing tumor cell due to) is arranged, effects such as diuresis, analgesic, analgesia, antiinflammatory are arranged.Its volatile oil has strong inhibitory action to pathogenic dermatophytes, decoct all has different inhibitory action to tubercule bacillus, diphtheria corynebacterium, anthrax bacillus, Bacillus typhi, paratyphoid bacillus A, bacillus pyocyaneus, escherichia coli, dysentery bacterium, bacillus subtilis, golden Staphylococcus aureus, meningococcus and influenza virus, and leptospira is had killing action.Herba Artemisiae Scopariae is the key medicine of treatment icterohepatitis, the active ingredient of its function of gallbladder promoting has kind more than ten through separation and evaluation, mainly be 6, the 7-dimethoxy coumarin, capillarisin, acid in the capillene, capillin, capillene, chlorogenic acid, caffeic acid, parahydroxyacet-ophenone etc., wherein capillarisin is strong function of gallbladder promoting composition, 6, the 7-dimethoxy coumarin can promote bile acid secretion, and acid in capillarisin, the capillene, capillin, capillene and volatile oil component all can increase choleresis, but little to the bile acid secretion influence.The observation in vitro Herba Artemisiae Scopariae has inhibitory action to the Respirovirus cytopathogenic effect.When the result shows 1: 10 concentration of BINHAO EcndII virus is had inhibitory action, inhibiting experiment in vitro result shows to hepatitis B virus, and Herba Artemisiae Scopariae decocting liquid is slight inhibitory action to HbsAg.
Rhizoma Polygoni Cuspidati can suppress hepatitis A virus, and hbs antigen is also had the obvious suppression effect, is used for the treatment of acute icterohepatitis curative effect the best clinically, and chronic persistent hepatitis is also had certain curative effect.Rhizoma Polygoni Cuspidati is to the 6.8-1 of the section strain of first type capital, influenza virus Asia, Orphan virus, herpes simplex virus, adenovirus IV type, poliomyelitis II type, enterovirus COxsackie A, B group and ECHO group, viruses such as encephalitis B Jing Wei grinds I number all have stronger inhibitory action, can be used for treating these viral diseases clinically, to staphylococcus aureus, Staphylococcus albus, micrococcus catarrhalis, streptococcus, escherichia coli, Bacillus proteus, bacillus pyocyaneus, Bacillus typhi, shigella flexneris etc. have inhibitory action, leptospira there is killing action, the effect of the serum glutamic pyruvic transminase of reduction is arranged.
Herba Hyperici Japonici has hepatoprotective effect, and the hepatic injury that carbon tetrachloride is caused has the certain protection effect, and dose dependent is arranged, and can obviously recover the reduction of the liver cell pigment P-450 content due to the carbon tetrachloride, hepatocyte is played the protective effect of micro structure RER and SER.Liver cell pigment P-450 is the enzyme system that plays a crucial role in the body detoxification processes, and Herba Hyperici Japonici helps liver to its protective effect and brings into play better Detoxication, and is even more important when especially this enzyme system of hepatic lesions is got involved.
Have the clinical symptoms of improvement, liver function normalization rate height, especially fall fast, the advantage such as comparatively stable after descending of enzyme with the scutellaria for treating viral hepatitis, can increase and exempt from the bile output greatly, and the effect of reduction blood mesobilirubin is arranged.Baicalin has Detoxication to white mice carbon tetrachloride poisoning liver injury, and baicalin has the effect of falling ALT.Radix Scutellariae has wider antimicrobial spectrum, multiple Gram-positive and negative bacteria all there is inhibitory action, decoct has in various degree antibacterial action to staphylococcus aureus, streptococcus pneumoniae, Hemolytic streptococcus, diphtheria corynebacterium, Bacillus proteus, vibrio cholera etc., for influenza virus and dermatophytes inhibitory action is also arranged, the high concentration amount has killing action to leptospira.
Poria has immunologic enhancement; can significantly improve the phagocytic function of Turnover of Mouse Peritoneal Macrophages; leukocyte is obviously risen; can impel mouse thymus and lymph node obviously to increase; can significantly improve rosette formation rate and lymhocyte transformation rate; can significantly increase serum IgG content; the effect and the hepatoprotective effect that promote cellular immunization and humoral immunization are arranged; rats'liver damage due to the carbon tetrachloride there is protective effect; can reduce the glutamate pyruvate transaminase vigor; prevent hepatic necrosis, urine zoopery and clinic observation confirm that diuresis is arranged, and can impel sodium potassium chlorine to discharge.
As improvement, Chinese medicine composition of the present invention is made up of the following weight proportion raw material: Herba Artemisiae Scopariae 1-40, Rhizoma Polygoni Cuspidati 1-30, Herba Hyperici Japonici 1-30, Radix Scutellariae 1-22, Poria 1-28, Herba Verbenae 1-30.
As further improvement, Chinese medicine composition of the present invention is made up of the following weight proportion raw material: Herba Artemisiae Scopariae 1-40, Rhizoma Polygoni Cuspidati 1-30, Herba Hyperici Japonici 1-30, Radix Scutellariae 1-22, Poria 1-28, Herba Verbenae 1-30, Herba Hydrocotyles 1-30.
As step improvement again, Chinese medicine composition of the present invention is made up of the following weight proportion raw material: Herba Artemisiae Scopariae 1-40, and Rhizoma Polygoni Cuspidati 1-30, Herba Hyperici Japonici 1-30, Radix Scutellariae 1-22, Poria 1-28, Herba Verbenae 1-30, Herba Hydrocotyles 1-30, holds 1-25.
As better improvement, Chinese medicine composition of the present invention is made up of the following weight proportion raw material: Herba Artemisiae Scopariae 1-40, and Rhizoma Polygoni Cuspidati 1-30, Herba Hyperici Japonici 1-30, Radix Scutellariae 1-22, Poria 1-28, Herba Verbenae 1-30, Herba Hydrocotyles 1-30, holds 1-25, Radix Gentianae 1-18.
As preferably, Chinese medicine composition of the present invention is made up of the following weight proportion raw material: Herba Artemisiae Scopariae 1-40, and Rhizoma Polygoni Cuspidati 1-30, Herba Hyperici Japonici 1-30, Radix Scutellariae 1-22, Poria 1-28, Herba Verbenae 1-30, Herba Hydrocotyles 1-30, holds 1-25, Radix Gentianae 1-18, Herba Rabdosiae Lophanthoidis 1-25.
As further preferred, Chinese medicine composition of the present invention is made up of the following weight proportion raw material: Herba Artemisiae Scopariae 1-40, Rhizoma Polygoni Cuspidati 1-30, Herba Hyperici Japonici 1-30, Radix Scutellariae 1-22, Poria 1-28, Herba Verbenae 1-30, Herba Hydrocotyles 1-30, holds 1-25, Radix Gentianae 1-18, Herba Rabdosiae Lophanthoidis 1-25, Rhizoma Alismatis 1-25.
As one going on foot preferably, Chinese medicine composition of the present invention is made up of the following weight proportion raw material: Herba Artemisiae Scopariae 1-40, Rhizoma Polygoni Cuspidati 1-30, Herba Hyperici Japonici 1-30, Radix Scutellariae 1-22 again, Poria 1-28, Herba Verbenae 1-30, Herba Hydrocotyles 1-30, holds 1-25, Radix Gentianae 1-18, Herba Rabdosiae Lophanthoidis 1-25, Rhizoma Alismatis 1-25, Herba Plantaginis 1-30.
The effect that Herba Hydrocotyles, hold, Radix Gentianae, Herba Rabdosiae Lophanthoidis, Rhizoma Alismatis, Herba Plantaginis all have clearing away heat-damp and promoting diuresis, depressed liver-energy dispersing and function of gallbladder promoting.
The present invention with reference to the modern pharmacological research achievement, with clinical use makes treatment hepatitis specific drug through research for many years based on secret prescription handed down in the family from generation to generation.Said herbal medicine forms through scientific compatibility, cure mainly the hepatitis disease (popular name: ascites hepatitis, food stagnation hepatitis, jaundice hepatitis) of the caused acute icteric infectious hepatitis of various hepatitis viruss, type b chronic non-icteric type infectious hepatitis etc. and other type, be used in particular for treating acute icterohepatitis, its therapeutic effect is remarkable, the medicine source is extensive, and is with low cost.
The Chinese herbal medicine porphyrize of above-mentioned compatibility is sieved after by scientific process is carried out packing, every bag (bag) 35 gram, every bag of (bag) child divides and takes for six times, and the adult divides four times, divides every day after meal, secondary is swallowed with eliminating cold for resuscitation water after the supper morning.
Period in a medicine is forbidden diet acid, peppery, cigarette, wine, chicken, Oryza glutinosa, dried small shrimps and stodgy rice cake rice cake etc. and dry weight physical work, avoids clothes Folium Camelliae sinensis, Semen Glycines, fresh hen egg, preserved egg, river Eriocheir sinensis, tonic, Erythroculter ilishaeformis, Semen Phaseoli radiati Germinatus etc.
Clinical case statistics through system, effective more than 98 to the treatment acute icterohepatitis, now be exemplified below:
One: one 33 years old male patient of case, therapeutic effect is not good through how tame medical institutions, do not obey medicine of the present invention before, biochemical investigation report: glutamate pyruvate transaminase 455, glutamic oxaloacetic transaminase, GOT 497, albumin 32.5, globulin ratio 1.08, total bilirubin 441.5, bilirubin direct 225.9, TOTAL BILE ACID TBA 106.3, glutamyl-transpeptidase 91, alkali phosphatase 197, lactic acid dehydrogenase 268, hepatitis b surface antigen positive.Through 51 days clothes Drug therapy of the present invention, liver function, two double full recoveries are normal, biochemical investigation report: glutamate pyruvate transaminase 13, glutamic oxaloacetic transaminase, GOT 39, albumin 42, globulin ratio 36.1, total bilirubin 23.7, bilirubin direct 12.9, unconjugated bilirubin 10.8, glutamyl transpeptidase 58, alkali phosphatase 139, lactic acid dehydrogenase 154, hepatitis b surface antigen positive 1: 32 is followed up a case by regular visits to and was not seen recurrence in 3 years.
Two: one 30 years old male patients of case, loss of appetite, gastral cavity side of body distension, spiritlessness and weakness, whole skin xanthochromia, 39 ℃ of body temperature, through biochemical investigation: glutamate pyruvate transaminase 395, GOT2 70, globulin 37, total bilirubin 49.4, bilirubin direct 27, two double, hepatitis b surface antigen positive 1: 512, the e antibody positive, core antibody positive.Through western medical treatment 20 days, every day, total bilirubin raise, and curative effect is little, through biochemical investigation: glutamate pyruvate transaminase 459, GOT2 27, globulin 39.4, total bilirubin 237.4, bilirubin direct 171.1, hepatitis b surface antigen positive 1: 256, e antibody positive, core antibody positive.Through 20 days clothes Drug therapy of the present invention, liver function test list: glutamate pyruvate transaminase 37, GOT2 8, total bilirubin 59, bilirubin direct 43, hepatitis b surface antigen positive 1: 64, e antibody positive, core antibody positive.Through 20 days medication treatment, liver function recovery was normal again, and two double, hepatitis b surface antigen positive 1: 16, e antibody positive, core antibody positive.Continue treatment half a year, liver function is normal, two double normal, follow up a case by regular visits to and do not see recurrence in 2 years.
Three: one 37 years old female patients of case are through biochemical investigation: glutamate pyruvate transaminase 258, glutamate-oxaloacetate transaminase 27, bilirubin direct 121, two double, hepatitis b surface antigen positive 1: 256, e antibody positive, core antibody positive.Through 1 month clothes Drug therapy of the present invention, liver function is normal, and two double, hepatitis b surface antigen positive 1: 64, e antibody positive, core antibody positive.Through the medication treatment in 1 year, liver function recovery was normal again, and two double, hepatitis b surface antigen positive 1: 16, e antibody positive, core antibody positive.Continue treatment half a year, two double normal, follow up a case by regular visits to and do not see recurrence in 10 years.
Four: one 27 years old male patients of case are through biochemical investigation: glutamate pyruvate transaminase 1847, glutamate-oxaloacetate transaminase 473, total bilirubin 728, bilirubin direct 312.Through 1 month clothes Drug therapy of the present invention, liver function: glutamate pyruvate transaminase 586, glutamic oxaloacetic transaminase, GOT 610, total bilirubin 127, bilirubin direct 82.25 days medication treatment again, liver function: glutamate pyruvate transaminase is normal, and glutamic oxaloacetic transaminase, GOT is normal, and total bilirubin is normal, and bilirubin direct is normal.Follow up a case by regular visits to and do not see recurrence in 2 years.
Five: one 28 years old male patients of case are through biochemical investigation: glutamate pyruvate transaminase 1920, glutamate-oxaloacetate transaminase 410, total bilirubin 1850, bilirubin direct 417, unconjugated bilirubin 145, glutamyl transpeptidase 186.Through 1 month clothes Drug therapy of the present invention, liver function: glutamate pyruvate transaminase 40, glutamic oxaloacetic transaminase, GOT 36, total bilirubin 125, bilirubin direct 27, unconjugated bilirubin 13.3.Through 10 days medication treatment, liver function was all normal again, followed up a case by regular visits to and did not see recurrence in 2 years.
Six: one 38 years old female patients of case are through biochemical investigation: glutamate pyruvate transaminase 480, GOT2 17, total bilirubin 176.Through the clothes Drug therapy of the present invention of two weeks, the liver function full recovery is normal, follows up a case by regular visits to and does not see recurrence in 2 years.
Seven: one 75 years old male patients of case are through biochemical investigation: glutamate pyruvate transaminase 2427, glutamate-oxaloacetate transaminase 728, total bilirubin 1895.Through 1 month clothes Drug therapy of the present invention, the liver function full recovery is normal, follows up a case by regular visits to and does not see recurrence in 1 year.
Four, the specific embodiment
Embodiment one: a kind of Chinese medicine composition for the treatment of acute icterohepatitis, (unit: gram) raw material is formed: Herba Artemisiae Scopariae 30, Rhizoma Polygoni Cuspidati 20, Herba Hyperici Japonici 20, Radix Scutellariae 12, Poria 18 by following each raw material for it.
Embodiment two: a kind of Chinese medicine composition for the treatment of acute icterohepatitis, (unit: gram) raw material is formed: Herba Artemisiae Scopariae 30, Rhizoma Polygoni Cuspidati 20, Herba Hyperici Japonici 20, Radix Scutellariae 12, Poria 18, Herba Verbenae 20 by following each raw material for it.
Embodiment three: a kind of Chinese medicine composition for the treatment of acute icterohepatitis, (unit: gram) raw material is formed: Herba Artemisiae Scopariae 30, Rhizoma Polygoni Cuspidati 20, Herba Hyperici Japonici 20, Radix Scutellariae 12, Poria 18, Herba Verbenae 20, Herba Hydrocotyles 20 by following each raw material for it.
Embodiment four: a kind of Chinese medicine composition for the treatment of acute icterohepatitis, and it is made up of following each raw material (unit: restrain) raw material: Herba Artemisiae Scopariae 30, Rhizoma Polygoni Cuspidati 20, Herba Hyperici Japonici 20, Radix Scutellariae 12, Poria 18, Herba Verbenae 20, Herba Hydrocotyles 20, holds 15.
Embodiment five: a kind of Chinese medicine composition for the treatment of acute icterohepatitis, and it is made up of following each raw material (unit: restrain) raw material: Herba Artemisiae Scopariae 30, Rhizoma Polygoni Cuspidati 20, Herba Hyperici Japonici 20, Radix Scutellariae 12, Poria 18, Herba Verbenae 20, Herba Hydrocotyles 20, holds 15, Radix Gentianae 8.
Embodiment six: a kind of Chinese medicine composition for the treatment of acute icterohepatitis, and it is made up of following each raw material (unit: restrain) raw material: Herba Artemisiae Scopariae 30, Rhizoma Polygoni Cuspidati 20, Herba Hyperici Japonici 20, Radix Scutellariae 12, Poria 18, Herba Verbenae 20, Herba Hydrocotyles 20, holds 15, Radix Gentianae 8, Herba Rabdosiae Lophanthoidis 15.
Embodiment seven: a kind of Chinese medicine composition for the treatment of acute icterohepatitis, and (unit: gram) raw material is formed: Herba Artemisiae Scopariae 30, Rhizoma Polygoni Cuspidati 20, Herba Hyperici Japonici 20 by following each raw material for it, Radix Scutellariae 12, Poria 18, Herba Verbenae 20, Herba Hydrocotyles 20, holds 15, Radix Gentianae 8, Herba Rabdosiae Lophanthoidis 15, Rhizoma Alismatis 15.
Embodiment eight: a kind of Chinese medicine composition for the treatment of acute icterohepatitis, and (unit: gram) raw material is formed: Herba Artemisiae Scopariae 30, Rhizoma Polygoni Cuspidati 20, Herba Hyperici Japonici 20, Radix Scutellariae 12 by following each raw material for it, Poria 18, Herba Verbenae 20, Herba Hydrocotyles 20, holds 15, Radix Gentianae 8, Herba Rabdosiae Lophanthoidis 15, Rhizoma Alismatis 15, Herba Plantaginis 20.
Claims (8)
1, a kind of Chinese medicine composition for the treatment of acute icterohepatitis, it is characterized in that: it is made up of the following weight proportion raw material: Herba Artemisiae Scopariae 1-40, Rhizoma Polygoni Cuspidati 1-30, Herba Hyperici Japonici 1-30, Radix Scutellariae 1-22, Poria 1-28.
2, a kind of Chinese medicine composition for the treatment of acute icterohepatitis according to claim 1, it is characterized in that: it is made up of the following weight proportion raw material: Herba Artemisiae Scopariae 1-40, Rhizoma Polygoni Cuspidati 1-30, Herba Hyperici Japonici 1-30, Radix Scutellariae 1-22, Poria 1-28, Herba Verbenae 1-30.
3, a kind of Chinese medicine composition for the treatment of acute icterohepatitis according to claim 1, it is characterized in that: it is made up of the following weight proportion raw material: Herba Artemisiae Scopariae 1-40, Rhizoma Polygoni Cuspidati 1-30, Herba Hyperici Japonici 1-30, Radix Scutellariae 1-22, Poria 1-28, Herba Verbenae 1-30, Herba Hydrocotyles 1-30.
4, a kind of Chinese medicine composition for the treatment of acute icterohepatitis according to claim 1, it is characterized in that: it is made up of the following weight proportion raw material: Herba Artemisiae Scopariae 1-40, Rhizoma Polygoni Cuspidati 1-30, Herba Hyperici Japonici 1-30, Radix Scutellariae 1-22, Poria 1-28, Herba Verbenae 1-30, Herba Hydrocotyles 1-30, holds 1-25.
5, a kind of Chinese medicine composition for the treatment of acute icterohepatitis according to claim 1, it is characterized in that: it is made up of the following weight proportion raw material: Herba Artemisiae Scopariae 1-40, Rhizoma Polygoni Cuspidati 1-30, Herba Hyperici Japonici 1-30, Radix Scutellariae 1-22, Poria 1-28, Herba Verbenae 1-30, Herba Hydrocotyles 1-30, holds 1-25, Radix Gentianae 1-18.
6, a kind of Chinese medicine composition for the treatment of acute icterohepatitis according to claim 1, it is characterized in that: it is made up of the following weight proportion raw material: Herba Artemisiae Scopariae 1-40, Rhizoma Polygoni Cuspidati 1-30, Herba Hyperici Japonici 1-30, Radix Scutellariae 1-22, Poria 1-28, Herba Verbenae 1-30, Herba Hydrocotyles 1-30, holds 1-25, Radix Gentianae 1-18, Herba Rabdosiae Lophanthoidis 1-25.
7, a kind of Chinese medicine composition for the treatment of acute icterohepatitis according to claim 1, it is characterized in that: it is made up of the following weight proportion raw material: Herba Artemisiae Scopariae 1-40, Rhizoma Polygoni Cuspidati 1-30, Herba Hyperici Japonici 1-30, Radix Scutellariae 1-22, Poria 1-28, Herba Verbenae 1-30, Herba Hydrocotyles 1-30, holds 1-25, Radix Gentianae 1-18, Herba Rabdosiae Lophanthoidis 1-25, Rhizoma Alismatis 1-25.
8, a kind of Chinese medicine composition for the treatment of acute icterohepatitis according to claim 1, it is characterized in that: it is made up of the following weight proportion raw material: Herba Artemisiae Scopariae 1-40, Rhizoma Polygoni Cuspidati 1-30, Herba Hyperici Japonici 1-30, Radix Scutellariae 1-22, Poria 1-28, Herba Verbenae 1-30, Herba Hydrocotyles 1-30, holds 1-25, Radix Gentianae 1-18, Herba Rabdosiae Lophanthoidis 1-25, Rhizoma Alismatis 1-25, Herba Plantaginis 1-30.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100498978A CN1329047C (en) | 2005-05-29 | 2005-05-29 | Chinese medicinal composition for treating acute icterohepatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100498978A CN1329047C (en) | 2005-05-29 | 2005-05-29 | Chinese medicinal composition for treating acute icterohepatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1720965A true CN1720965A (en) | 2006-01-18 |
| CN1329047C CN1329047C (en) | 2007-08-01 |
Family
ID=35911802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100498978A Expired - Fee Related CN1329047C (en) | 2005-05-29 | 2005-05-29 | Chinese medicinal composition for treating acute icterohepatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1329047C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101244158B (en) * | 2008-03-10 | 2012-01-25 | 李义初 | Chinese medicinal herb for effectively treating cirrhosis, liver ascites |
| CN104147270A (en) * | 2014-08-28 | 2014-11-19 | 广西梧州三鹤药业有限公司 | Traditional Chinese medicine for treating acute hepatitis |
| CN104623500A (en) * | 2015-01-26 | 2015-05-20 | 陆宇 | Pharmaceutical composition for treating cholestatic hepatitis |
| CN104721352A (en) * | 2014-12-20 | 2015-06-24 | 熊安富 | Traditional Chinese medicine for treating acute/chronic hepatitis and cholecystitis |
| CN104800397A (en) * | 2015-05-14 | 2015-07-29 | 张瑞花 | Medicine composition used for treating neonatal jaundice |
| CN105434636A (en) * | 2015-12-21 | 2016-03-30 | 天农大（天津）生物科技有限公司 | Traditional Chinese medicine composition used for treating duckling hepatitis, and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1271604A (en) * | 1999-04-27 | 2000-11-01 | 王清 | Oral liquid for curing hepatitis |
| CN1579427A (en) * | 2003-08-14 | 2005-02-16 | 李锡宽 | Traditional Chinese medicine for treating hepatitis B and its preparation method |
-
2005
- 2005-05-29 CN CNB2005100498978A patent/CN1329047C/en not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101244158B (en) * | 2008-03-10 | 2012-01-25 | 李义初 | Chinese medicinal herb for effectively treating cirrhosis, liver ascites |
| CN104147270A (en) * | 2014-08-28 | 2014-11-19 | 广西梧州三鹤药业有限公司 | Traditional Chinese medicine for treating acute hepatitis |
| CN104147270B (en) * | 2014-08-28 | 2017-11-17 | 广西梧州三鹤药业有限公司 | Treat the Chinese medicine composition of oxyhepatitis |
| CN104721352A (en) * | 2014-12-20 | 2015-06-24 | 熊安富 | Traditional Chinese medicine for treating acute/chronic hepatitis and cholecystitis |
| CN104721352B (en) * | 2014-12-20 | 2018-03-16 | 熊安富 | A kind of Chinese medicine for treating hepatitis B |
| CN104623500A (en) * | 2015-01-26 | 2015-05-20 | 陆宇 | Pharmaceutical composition for treating cholestatic hepatitis |
| CN104800397A (en) * | 2015-05-14 | 2015-07-29 | 张瑞花 | Medicine composition used for treating neonatal jaundice |
| CN105434636A (en) * | 2015-12-21 | 2016-03-30 | 天农大（天津）生物科技有限公司 | Traditional Chinese medicine composition used for treating duckling hepatitis, and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1329047C (en) | 2007-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1081067C (en) | Chinese medicine prescription for curing hepatitis, cholangitis, pancreatitis and cirrhosis | |
| MXPA03003446A (en) | Novel medicinal herbal composition for treating liver diseases and hiv. | |
| CN1329047C (en) | Chinese medicinal composition for treating acute icterohepatitis | |
| CN100444863C (en) | Chinese medicine composition for diminishing-inflammation and detoxication and its preparing method and use | |
| CN101711796B (en) | Application of scullcapflavone in preparing medicament for treating enterovirus infection | |
| CN104013756B (en) | A kind of Chinese medicine composition for preventing and treating diarrhoea and application thereof | |
| CN101040945A (en) | Chinese traditional medicine compound took orally for creating bacterial dysentery | |
| CN1698812A (en) | Pharmaceutical composition for treating hepatitis B | |
| CN116139237B (en) | A Chinese medicinal composition for preventing and treating respiratory tract infection caused by coronavirus, and its application | |
| CN100546618C (en) | The psoriatic Chinese medicine preparation of a kind of treatment | |
| CN111700998A (en) | Application of compound Chinese patent medicine in treating pneumonia COVID-19 infected by novel coronavirus | |
| CN1404868A (en) | Chinese medicinal preparation for treating pyretic stranguria | |
| CN104623379B (en) | A kind of pharmaceutical composition for the treatment of Hand-Food-Mouth Disease | |
| CN1985902B (en) | Chinese medicine for treating chronic hepatopathy | |
| CN109700976B (en) | Qie and zedoary liver-protecting paste | |
| CN104623217A (en) | Traditional Chinese medicine preparation for treating asthma and preparation method thereof | |
| CN100415277C (en) | A Chinese traditional medicinal preparation for treatment of psoriasis | |
| CN104116960A (en) | Traditional Chinese medicinal preparation for treating hand-foot-and-mouth disease | |
| CN113476542B (en) | Application of composition in preparation of medicines and kits | |
| CN102406906A (en) | Traditional Chinese medicine composition for treating acute hepatitis B | |
| CN100546623C (en) | The psoriatic Chinese medicine preparation of a kind of treatment | |
| CN1931311A (en) | Psoriasis treating Chinese medicine prepn | |
| CN101028352A (en) | Chinese-medicinal preparation for treating ischiodynia | |
| CN1103599C (en) | Chenxia medicament for relieving asthma and its pren. tech. | |
| Xu | TCM and Western Medicine: Diagnosis and Treatment of Novel Coronavirus Pneumonia, A Case Study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070801 Termination date: 20130529 |